Literature DB >> 24112742

Can we improve the definition of high-risk, hormone naïve, non-metastatic prostate cancer?

Bertrand Tombal1, Antonio Alcaraz, Nicholas James, Riccardo Valdagni, Jacques Irani.   

Abstract

To identify criteria beyond Tumour-Node-Metastasis (TMN)-, prostate-specific antigen (PSA)- and Gleason score-based standard classifications to enhance the stratification of non-metastatic high-risk prostate cancer. A detailed search of the literature was performed using PubMed. The authors reviewed the literature and used a modified Delphi approach to identify relevant approaches to enhance standard classifications. Specific criteria for high-risk prostate cancer vary across guidelines and clinical trials, reflecting the differing perspectives concerning the definition of 'risk' between different specialities within the urology/radiation oncology community. In addition to the present classifications, evidence exists that the measure of cancer volume can provide additional prognostic value. More accurate imaging, especially multiparametric magnetic resonance imaging can also provide information concerning staging and cancer volume, and thus may assist in the identification of patients with high-risk prostate cancer. A refined definition of non-metastatic high-risk prostate cancer is proposed. Within this high-risk cohort, patients with multiple high-risk criteria are especially at risk of prostate cancer-specific mortality.
© 2013 The Authors. BJU International © 2013 BJU International.

Entities:  

Keywords:  high-risk prostate cancer; prostate cancer; risk stratification

Mesh:

Substances:

Year:  2014        PMID: 24112742     DOI: 10.1111/bju.12469

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  3 in total

1.  Whole-body MRI to assess bone involvement in prostate cancer and multiple myeloma: comparison of the diagnostic accuracies of the T1, short tau inversion recovery (STIR), and high b-values diffusion-weighted imaging (DWI) sequences.

Authors:  Ahmed Larbi; Patrick Omoumi; Vassiliki Pasoglou; Nicolas Michoux; Perrine Triqueneaux; Bertrand Tombal; Catherine Cyteval; Frédéric E Lecouvet
Journal:  Eur Radiol       Date:  2018-11-09       Impact factor: 5.315

2.  Epithelial-mesenchymal transition in prostate cancer is associated with quantifiable changes in nuclear structure.

Authors:  James E Verdone; Princy Parsana; Robert W Veltri; Kenneth J Pienta
Journal:  Prostate       Date:  2014-10-18       Impact factor: 4.104

3.  Formal consensus method to evaluate the conformity of prescription of a recently approved chemotherapy treatment in an observatory study.

Authors:  Nadine Houédé; Eric Leutenegger; Mariella Lomma; Carine Bellera
Journal:  PLoS One       Date:  2015-04-02       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.